Oncodesign

What Oncodesign does

Oncodesign Precision Medicine (OPM) is a publicly listed French biopharmaceutical company (Euronext Growth Paris: ALOPM; ISIN FR001400CM63) headquartered in Dijon that discovers and develops first-in-class and best-in-class kinase-inhibitor drug candidates for oncology, inflammatory bowel disease (IBD), Parkinson's disease, and central nervous system disorders. The company was created in July 2022 when the original Oncodesign (founded 1995 by Philippe Genne) split into two entities; the services arm was sold to Elyan Partners (advised by Edmond de Rothschild) while the biotech and AI activities were transferred into OPM, which then listed via direct listing on Euronext Access+ Paris in October 2022.

OPM's technology stack combines three proprietary platforms. Nanocyclix®, introduced around 2010 by CSO Jan Hoflack, is a medicinal chemistry platform using macrocyclization of small molecules to generate potent and selective kinase inhibitors and underpins the lead assets OPM-101 (RIPK2 inhibitor) and OPM-201 (LRRK2 inhibitor). OncoSNIPER® is an AI-powered platform for therapeutic target identification and patient stratification, fed by the OncoSNIPE multimodal clinical/molecular dataset of 600 patients across 16 partner institutions and managed via InterSystems IRIS for Health. PROMETHE® is a theranostics platform for design of radiolabeled biological molecules for systemic radiotherapy, supporting the COMETE program (metastatic colorectal/gastric cancers) and the Florepizol PET radiotracer.

As a pre-commercial biopharma, OPM is not generating product revenue; its capital base is built on a mix of grant funding (€2.1M ERDF for COMETE, €5.6M DEMOCRITE public funding for OPM-101 in IBD, Deep Tech / ANIMUS funding, and a $6.92M / ~€5.84M grant from The Michael J. Fox Foundation for OPM-201), €6M of Bpifrance-guaranteed bank financing (October 2023), small equity capital increases (~€2M in February 2024 and up to €5M in April 2025), and historical licensing income from prior partnerships with Servier (now largely reacquired) and SEngine Precision Medicine. The commercial model targets co-development and out-licensing arrangements with global pharmaceutical partners; OPM-201's reacquisition from Servier in December 2024 signals a shift toward retaining more downstream value and seeking new partners, while a January 2026 Ksilink collaboration opens a CNS vertical.

Name

Oncodesign

Legal name

Oncodesign Precision Medicine

Website

https://oncodesign.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Oncodesign Precision Medicine (OPM) is a Dijon-based, Euronext Growth-listed biopharmaceutical company that develops first-in-class kinase-inhibitor drug candidates using proprietary Nanocyclix® chemistry, AI-powered OncoSNIPER® target identification, and PROMETHE® radiotheranostics for oncology, IBD, and Parkinson's disease.

Ownership category

akta.pro rank

Product category

Precision Medicine Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Precision medicine therapeutics
• Kinase inhibitor discovery
• Clinical-stage biopharmaceutical
• Radiotheranostics development
• AI-powered drug discovery

Headquarters

HQ city

Dijon

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Partnership/Licensing Revenue: OPM generates revenue through strategic partnerships with pharmaceutical companies including milestone payments, licensing fees, and royalty streams. Key partnerships include Servier (LRRK2 inhibitor OPM-201 for Parkinson's disease, STarT pancreatic cancer program), SEngine Precision Medicine (oncology), and others. The company retains rights to its drug candidates and seeks partnerships for co-development and commercialization.
2. Grant Funding: Non-dilutive funding from foundations and government programs. $6.92M grant from Michael J. Fox Foundation for OPM-201 clinical development, €5.6M DEMOCRITE program funding for OPM-101, €2.1M ERDF funding for COMETE program, Deep Tech Development funding for ANIMUS program.
3. Bank Financing: Non-dilutive bank financing of €6M secured from regional banks (Caisse d'Épargne Bourgogne Franche Comté, Crédit Agricole de Champagne Bourgogne, Société Générale) guaranteed by Bpifrance.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Oncodesign Precision Medicine is a clinical-stage biopharmaceutical company that discovers and develops precision medicine drug candidates, primarily kinase inhibitors, for oncology, neurodegeneration and inflammatory diseases. Its offering is anchored on three proprietary platforms — OncoSNIPER (AI target identification), Nanocyclix (macrocyclic medicinal chemistry) and PROMETHE (radiotheranostics) — and commercialized through pharmaceutical partnerships, licensing and co-development rather than direct product sales.

Product overview

Oncodesign Precision Medicine is a biopharmaceutical company built on a proprietary technology platform combining AI-powered target identification (OncoSNIPER), macrocyclic kinase inhibitor discovery (Nanocyclix®), and radiotheranostics (PROMETHE®). The company operates two clinical-stage drug candidates: OPM-101 (RIPK2 inhibitor) advancing in oncology and inflammatory bowel disease, and OPM-201 (LRRK2 inhibitor) for Parkinson's disease. Additional programs include the COMETE radiotherapy initiative and the Florepizol EGFR radiotracer. The company generates revenue through service offerings and seeks to license its proprietary molecules to pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

• OncoSNIPER: AI-powered platform for selection of therapeutic targets in precision medicine
• Nanocyclix
• PROMETHE
• OPM-101
• OPM-201

Products and services

• OPM-101 (RIPK2 inhibitor) Clinical-stage RIPK2 kinase inhibitor drug candidate in development for advanced melanoma with resistance to anti-PD-1 (REVERT Phase 1b/2a study, protocol submitted March 2025) and for inflammatory bowel disease through the DEMOCRITE program, positioning OPM in both oncology and immuno-inflammatory indications.
• OPM-201 (LRRK2 inhibitor) Clinical-stage macrocyclic LRRK2 kinase inhibitor drug candidate for Parkinson's disease targeting patients with LRRK2 mutations, with completed Phase 1 in healthy volunteers, integration into the Michael J. Fox Foundation LITE program, $6.92M MJFF grant for Phase 1b/2, and planned Phase 1b/2 clinical trials in 2027.
• Nanocyclix Technology Platform Proprietary medicinal chemistry platform based on macrocyclization of small molecules used to discover highly potent and selective macrocyclic kinase inhibitors addressing kinases involved in over 400 diseases, available to pharmaceutical and biotech partners through licensing, co-development and library-screening collaborations.
• OncoSNIPER AI Platform AI-powered platform for the identification and validation of therapeutic targets in precision medicine, integrating clinical and molecular data through the InterSystems IRIS for Health platform to guide patient stratification and target selection across OPM's pipeline and partner programs.
• PROMETHE Theranostics Platform Technology platform for the design and selection of radiolabeled biological molecules for systemic radiotherapy, enabling targeted radiation treatment of cancers and supporting the COMETE program for metastatic colorectal and gastric cancers.
• COMETE Molecular Radiotherapy Program Discovery and translational program in molecular radiotherapy for metastatic colorectal and gastric cancers, funded by a €2.1M ERDF grant and leveraging the PROMETHE platform.
• Florepizol EGFR PET Radiotracer PET radiotracer targeting mutated EGFR in non-small cell lung cancer patients that has successfully completed its first clinical study, a product of the PROMETHE theranostics platform.

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• KsilinkcoreStrategic or Co-development Partner · 8 January 2026Collaboration launched January 2026 to test Nanocyclix chemical library in patient-derived cell models for serious central nervous system diseases. Ksilink provides high-throughput phenotypic screening platform using cells derived from patients.
• Navigo Proteins GmbHminorStrategic or Co-development Partner · 15 May 2024Strategic collaboration for research and development of new systemic radiotherapy agents. Announced May 2024; terminated December 2025 due to resource optimization and challenges with initial target selection. Both parties pursuing separate development pathways.
• FederAidd ConsortiumcoreStrategic or Co-development Partner · 15 December 2022International virtual campus for open innovation in AI-driven Drug Discovery. Co-founded by OPM and Servier to interconnect pharma, biotechs, CROs, AI startups, academic institutes, hospitals, and IT providers. Governed by association law 1901.
• SEngine Precision MedicinecoreStrategic or Co-development Partner · 8 February 2022Research collaboration to discover new personalized cancer treatment for aggressive and untreatable tumors. Combines SEngine's PARIS Test platform for drug screening on patient-derived tumor cells with Oncodesign's Nanocyclix technology for kinase inhibitors. SEngine provides research funding for initial compound optimization with option for larger collaboration.
• TiumBiominorStrategic or Co-development Partner · 1 October 2021Strategic R&D collaboration signed October 2021 to identify new drug candidates to treat fibrosis. Oncodesign contributes its Nanocyclix technology and drug discovery expertise to the partnership.
• InterSystemscoreTechnology or Integration · 18 May 2021Long-term partnership for data optimization in drug discovery. Oncodesign uses InterSystems IRIS for Health platform for organizing and leveraging healthcare data to accelerate oncology research using AI. Integration into AI Business Unit for storage and management of preclinical and clinical data.
• ServiercoreStrategic or Co-development Partner · 1 March 2019Strategic R&D collaboration started March 2019 to identify new drug candidate for Parkinson's disease. Servier exercised exclusive worldwide license option for LRRK2 inhibitor (OPM-201) with Phase 1 study in healthy volunteers. In December 2024, OPM reacquired all rights to OPM-201 program. Continued collaboration includes STarT project for pancreatic cancer (September 2022) and FederAidd AI campus (December 2022).

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Others

• Servier: Servier is a French mid-sized global pharmaceutical company that was OPM's original partner on the LRRK2 inhibitor OPM-201 (rights reacquired in December 2024) and continues to collaborate on STarT pancreatic cancer and the FederAidd AI campus. Functions as a peer in the broader kinase inhibitor / precision oncology space and a continuing strategic partner for OPM.

Direct peers

• Denali Therapeutics: Denali Therapeutics is a clinical-stage biopharmaceutical company developing LRRK2 inhibitors for Parkinson's disease (DNL151/benvosetin), making it the most direct competitor to OPM's OPM-201 program. Both target genetically validated LRRK2 mutation carriers with brain-penetrant small molecules, serving the same patient population with similar therapeutic approaches.
• Kymera Therapeutics: Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies that target protein degradation (including kinase pathways) for cancer and immunology. Comparable as a similarly-sized US-based clinical-stage precision medicine company with platform technology and partnered programs.
• Point Biopharma (acquired by Eli Lilly): Point Biopharma was a clinical-stage radiopharmaceutical company developing targeted radioligand therapies for cancer, acquired by Eli Lilly in 2023. Closely comparable to OPM's PROMETHE theranostics platform and provides a benchmark valuation/liquidity outcome for radioligand-focused oncology platforms.
• Cerevel Therapeutics (acquired by AbbVie): Cerevel Therapeutics was a clinical-stage neuroscience-focused biopharmaceutical company developing therapies for Parkinson's disease and other CNS disorders, acquired by AbbVie in 2024. Comparable to OPM-201's CNS focus and demonstrates a credible exit path for CNS precision medicine biotechs targeting Parkinson's and related indications.

Broad incumbents

• AstraZeneca: AstraZeneca is a global pharmaceutical company with a large kinase inhibitor portfolio (TAGRISSO, CALQUENCE, LYNPARZA-adjacent) and CNS franchise. Jan Hoflack (OPM CSO) previously worked at AstraZeneca, and AZ is a potential strategic acquirer or partner for OPM programs given its scale in oncology and CNS.
• Blueprint Medicines: Blueprint Medicines is a commercial-stage precision therapy company focused on kinase inhibitors for cancer and rare diseases (e.g., AYVAKIT for systemic mastocytosis, GAVRETO for RET-altered cancers). It operates in the same kinase inhibitor precision oncology space as OPM but at much greater scale with approved products and broader portfolio.
• Roche: Roche is a global pharmaceutical leader with major oncology, neuroscience, and diagnostic franchises, including a strong radiopharmaceutical business. Represents a potential large-pharma acquirer for OPM's combined kinase/AI/theranostics platform, with interest in similar precision oncology and CNS indications OPM is pursuing.
• Mirati Therapeutics (acquired by BMS): Mirati Therapeutics was a clinical-to-commercial oncology company developing kinase-targeted therapies including KRAZATI (adagrasib) for KRAS-mutant cancers. Acquired by Bristol Myers Squibb in 2024, it represents a successful analog for kinase-focused precision oncology biotechs at the commercial stage OPM is targeting.

Emerging players

• SpringWorks Therapeutics: SpringWorks Therapeutics is a commercial-stage biopharmaceutical company focused on oncology and rare diseases, with multiple approved products (OGSIVEO for desmoid tumors, QINLOCK for GIST). Comparable as a precision oncology biotech that progressed from clinical-stage to commercialization, illustrating a viable growth trajectory for OPM to emulate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInfr.linkedin.com/company/oncodesign-precision-medicine
• Xx.com/oncodesignsa

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncodesign